FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947142015> ?p ?o ?g. }

• W2947142015 abstract "Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is approved, 5 mg twice daily (BID) is the recommended dose for PsA and RA. An important component of any product labelling is information on the need for laboratory monitoring. Objectives This post hoc analysis aimed to provide information on the effect of tofacitinib 5 mg BID on laboratory values in PsA and RA patients (pts). Methods For analysis of pts with active PsA treated with tofacitinib 5 mg BID, data were pooled from 2 Phase 3 studies and an ongoing long-term extension (LTE) study (data cut-off, 25 January 2017; database not locked; data may change). For analysis of pts with moderate or severe RA treated with tofacitinib 5 mg BID, data were pooled from 8 Phase 2, 7 Phase 3, and 1 LTE studies (data cut-off, 2 March 2017; for LTE, database not locked; data may change). All PsA and most RA pts received a background conventional synthetic disease-modifying antirheumatic drug. Data (to Month 12) for pts receiving constant tofacitinib 5 mg BID were evaluated, comprising pts who received tofacitinib 5 mg BID across studies, either at randomisation or following switch from placebo. Pts in the placebo groups who switched to tofacitinib 5 mg BID at Month 3 were included from the time they first received tofacitinib. Pts who switched tofacitinib dose were excluded. Change from baseline in haematologic (haemoglobin, neutrophils, lymphocytes) and lipid (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol, triglyceride) levels and key liver tests (bilirubin, alanine aminotransferase, aspartate aminotransferase) were analysed. Although not addressed in the product labelling, creatine kinase, creatinine and C-reactive protein levels were also assessed. Pts meeting protocol-defined discontinuation criteria for laboratory values were evaluated. Results The constant tofacitinib 5 mg BID group comprised 348 PsA pts and 3040 RA pts. Mean (standard error) changes/percentage changes from baseline for laboratory values are presented in the table. Laboratory values generally stabilised after 1 to 3 months, and lymphocyte levels stabilised by 24 months (data not shown). In both PsA and RA, ≤3.0% of patients met discontinuation criteria for any laboratory values. Conclusion In this post hoc analysis of laboratory data with tofacitinib 5 mg BID, changes in key laboratory values were similar for PsA and RA, and discontinuations due to protocol criteria being met for laboratory values were infrequent. These results provide further information on the effect of tofacitinib on laboratory values in PsA and RA. Acknowledgement This study was sponsored by Pfizer Inc. Medical writing support was provided by Karleen Nicholson, PhD, on behalf of CMC Connect, a division of McCann Health Medical Communications Ltd, Macclesfield, UK, and was funded by Pfizer Inc. Disclosure of Interests William Rigby Consultant for: Pfizer Inc, Gerd Rudiger Burmester Consultant for: Roche, Sanofi-Genzyme, Speakers bureau: Roche, Sanofi-Genzyme, Oliver FitzGerald: None declared, Valderilio F Azevedo Grant/research support from: AbbVie, GSK, Janssen, Merck Serono, Novartis, Pfizer Inc, UCB, Consultant for: AbbVie, GSK, Janssen, Merck Serono, Novartis, Pfizer Inc, UCB, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Daniela Graham Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Cunshan Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Thomas Jones Shareholder of: Pfizer Inc, Employee of: Pfizer Inc" @default.
• W2947142015 created "2019-06-07" @default.
• W2947142015 creator A5008763926 @default.
• W2947142015 creator A5017740190 @default.
• W2947142015 creator A5022208894 @default.
• W2947142015 creator A5073833664 @default.
• W2947142015 creator A5075200726 @default.
• W2947142015 creator A5077643606 @default.
• W2947142015 creator A5082474412 @default.
• W2947142015 creator A5089096514 @default.
• W2947142015 date "2019-05-27" @default.
• W2947142015 modified "2023-10-17" @default.
• W2947142015 title "AB0440 CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS" @default.
• W2947142015 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1290" @default.
• W2947142015 hasPublicationYear "2019" @default.
• W2947142015 type Work @default.
• W2947142015 sameAs 2947142015 @default.
• W2947142015 citedByCount "0" @default.
• W2947142015 crossrefType "proceedings-article" @default.
• W2947142015 hasAuthorship W2947142015A5008763926 @default.
• W2947142015 hasAuthorship W2947142015A5017740190 @default.
• W2947142015 hasAuthorship W2947142015A5022208894 @default.
• W2947142015 hasAuthorship W2947142015A5073833664 @default.
• W2947142015 hasAuthorship W2947142015A5075200726 @default.
• W2947142015 hasAuthorship W2947142015A5077643606 @default.
• W2947142015 hasAuthorship W2947142015A5082474412 @default.
• W2947142015 hasAuthorship W2947142015A5089096514 @default.
• W2947142015 hasBestOaLocation W29471420151 @default.
• W2947142015 hasConcept C126322002 @default.
• W2947142015 hasConcept C142724271 @default.
• W2947142015 hasConcept C204787440 @default.
• W2947142015 hasConcept C27081682 @default.
• W2947142015 hasConcept C2776233030 @default.
• W2947142015 hasConcept C2776260265 @default.
• W2947142015 hasConcept C2777575956 @default.
• W2947142015 hasConcept C2778886723 @default.
• W2947142015 hasConcept C71924100 @default.
• W2947142015 hasConcept C98274493 @default.
• W2947142015 hasConceptScore W2947142015C126322002 @default.
• W2947142015 hasConceptScore W2947142015C142724271 @default.
• W2947142015 hasConceptScore W2947142015C204787440 @default.
• W2947142015 hasConceptScore W2947142015C27081682 @default.
• W2947142015 hasConceptScore W2947142015C2776233030 @default.
• W2947142015 hasConceptScore W2947142015C2776260265 @default.
• W2947142015 hasConceptScore W2947142015C2777575956 @default.
• W2947142015 hasConceptScore W2947142015C2778886723 @default.
• W2947142015 hasConceptScore W2947142015C71924100 @default.
• W2947142015 hasConceptScore W2947142015C98274493 @default.
• W2947142015 hasLocation W29471420151 @default.
• W2947142015 hasOpenAccess W2947142015 @default.
• W2947142015 hasPrimaryLocation W29471420151 @default.
• W2947142015 hasRelatedWork W2335614809 @default.
• W2947142015 hasRelatedWork W2749276380 @default.
• W2947142015 hasRelatedWork W2751178115 @default.
• W2947142015 hasRelatedWork W2754043363 @default.
• W2947142015 hasRelatedWork W2754241130 @default.
• W2947142015 hasRelatedWork W2754454361 @default.
• W2947142015 hasRelatedWork W2755049090 @default.
• W2947142015 hasRelatedWork W2755836038 @default.
• W2947142015 hasRelatedWork W2894900585 @default.
• W2947142015 hasRelatedWork W2896812857 @default.
• W2947142015 hasRelatedWork W2900635510 @default.
• W2947142015 hasRelatedWork W2910347821 @default.
• W2947142015 hasRelatedWork W2910355860 @default.
• W2947142015 hasRelatedWork W2910517343 @default.
• W2947142015 hasRelatedWork W2950207837 @default.
• W2947142015 hasRelatedWork W2977680555 @default.
• W2947142015 hasRelatedWork W3092889157 @default.
• W2947142015 hasRelatedWork W3123452764 @default.
• W2947142015 hasRelatedWork W3164234380 @default.
• W2947142015 hasRelatedWork W3164788343 @default.
• W2947142015 isParatext "false" @default.
• W2947142015 isRetracted "false" @default.
• W2947142015 magId "2947142015" @default.
• W2947142015 workType "article" @default.